Allan David

Allan David serves as the John W. Brown Professor of Chemical Engineering and Associate Dean for Research at Auburn University's Samuel Ginn College of Engineering. His leadership extends across academic administration and cutting-edge nanomedicine research, with a focus on translating laboratory discoveries into clinical applications.

His educational foundation includes:

• Ph.D. in Chemical Engineering, University of Maryland
• B.S. in Chemical Engineering, University of Maryland

Dr. David's research program pioneers nanomedicine applications through the development of smart materials for cancer diagnostics and therapy. His work spans nanoparticle-based MRI contrast agents, ocular drug delivery systems, and vaccine delivery platforms, with particular emphasis on optimizing physicochemical properties for targeted biological interactions. Current projects address critical healthcare challenges including safer contrast agents for patients with kidney impairment and precision cancer targeting mechanisms.

Analysis of his 15 most recent publications reveals a cohesive research trajectory centered on magnetic nanoparticles and biomimetic delivery systems. The work demonstrates increasing translational focus, evolving from fundamental nanoparticle characterization (2020-2021) to clinically relevant applications like ocular delivery and cancer theranostics (2022-2024), culminating in commercialization efforts through NanoXort, LLC.

Dr. David has secured significant research funding including an $184,773 grant from the Alabama Department of Economic and Community Affairs (ADECA) for developing cardiovascular MRI agents. He leads collaborative efforts that bridge chemical engineering with biomedical innovation, notably co-founding NanoXort, LLC to commercialize safer MRI contrast agents addressing gadolinium toxicity concerns for renal-impaired patients.

His laboratory operates at the intersection of chemical engineering and medicine, focusing on nanoparticle-cell interactions and targeted delivery systems. The research group maintains strong industry partnerships through the NanoXort startup, which has secured $1 million NSF funding to advance MRI contrast agent technology toward clinical implementation.